Overview

Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme

Status:
Completed
Trial end date:
2017-06-19
Target enrollment:
Participant gender:
Summary
This study is evaluating the safety and pharmacokinetics of ABT-414 in subjects with glioblastoma multiforme.
Phase:
Phase 1
Details
Lead Sponsor:
AbbVie
Treatments:
Dacarbazine
Temozolomide